Tislelizumab (TIS) versus docetaxel (D) in patients with previously treated advanced squamous (sq) non-small-cell lung cancer (NSCLC): Sub-analysis from phase 3 RATIONALE-303 randomized clinical study | AVESİS

Kocaeli University Research Information System

Tislelizumab (TIS) versus docetaxel (D) in patients with previously treated advanced squamous (sq) non-small-cell lung cancer (NSCLC): Sub-analysis from phase 3 RATIONALE-303 randomized clinical study

Copy For Citation

Wang J., Ma Z., Huang D., Fan Y., Yu X., Hu S., ...More

Annual Meeting of the American-Association-for-Cancer-Research (AACR), Louisiana, United States Of America, 8 - 13 April 2022

Publication Type: Conference Paper / Summary Text
City: Louisiana
Country: United States Of America
Kocaeli University Affiliated: Yes